CN114214380A - 一种大豆咖啡西洋参生物活性肽的制备方法和应用 - Google Patents
一种大豆咖啡西洋参生物活性肽的制备方法和应用 Download PDFInfo
- Publication number
- CN114214380A CN114214380A CN202111544431.0A CN202111544431A CN114214380A CN 114214380 A CN114214380 A CN 114214380A CN 202111544431 A CN202111544431 A CN 202111544431A CN 114214380 A CN114214380 A CN 114214380A
- Authority
- CN
- China
- Prior art keywords
- soybean
- coffee
- american ginseng
- peptide
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000005373 Panax quinquefolius Species 0.000 title claims abstract description 53
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 53
- 244000068988 Glycine max Species 0.000 title claims abstract description 52
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 52
- 240000007154 Coffea arabica Species 0.000 title claims abstract description 51
- 235000016213 coffee Nutrition 0.000 title claims abstract description 51
- 235000013353 coffee beverage Nutrition 0.000 title claims abstract description 51
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 50
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 241000196324 Embryophyta Species 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 9
- 108090000790 Enzymes Proteins 0.000 claims abstract description 9
- 229940088598 enzyme Drugs 0.000 claims abstract description 9
- 230000000415 inactivating effect Effects 0.000 claims abstract description 7
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 6
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 6
- 102000004142 Trypsin Human genes 0.000 claims abstract description 6
- 108090000631 Trypsin Proteins 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 229940111202 pepsin Drugs 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 239000012588 trypsin Substances 0.000 claims abstract description 6
- 239000012670 alkaline solution Substances 0.000 claims abstract description 5
- 239000004382 Amylase Substances 0.000 claims abstract description 3
- 102000013142 Amylases Human genes 0.000 claims abstract description 3
- 108010065511 Amylases Proteins 0.000 claims abstract description 3
- 240000003183 Manihot esculenta Species 0.000 claims abstract description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims abstract description 3
- 108090000526 Papain Proteins 0.000 claims abstract description 3
- 239000004365 Protease Substances 0.000 claims abstract description 3
- 235000019418 amylase Nutrition 0.000 claims abstract description 3
- 229940055729 papain Drugs 0.000 claims abstract description 3
- 235000019834 papain Nutrition 0.000 claims abstract description 3
- 239000012460 protein solution Substances 0.000 claims abstract description 3
- 229960001322 trypsin Drugs 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002131 composite material Substances 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract description 3
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 abstract description 3
- 229960001948 caffeine Drugs 0.000 abstract description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000015654 memory Effects 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- 230000009084 cardiovascular function Effects 0.000 abstract description 2
- 230000002124 endocrine Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000035939 shock Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 235000013373 food additive Nutrition 0.000 description 12
- 239000002778 food additive Substances 0.000 description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 9
- 229930091371 Fructose Natural products 0.000 description 9
- 229960002737 fructose Drugs 0.000 description 9
- 239000005715 Fructose Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940080701 chymosin Drugs 0.000 description 6
- 108010007119 flavourzyme Proteins 0.000 description 6
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000145 Bacillolysin Proteins 0.000 description 4
- 235000005976 Citrus sinensis Nutrition 0.000 description 4
- 240000002319 Citrus sinensis Species 0.000 description 4
- 108091005507 Neutral proteases Proteins 0.000 description 4
- 102000035092 Neutral proteases Human genes 0.000 description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 229930189775 mogroside Natural products 0.000 description 4
- 229940013618 stevioside Drugs 0.000 description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 4
- 235000019202 steviosides Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108091005658 Basic proteases Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 244000148687 Glycosmis pentaphylla Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
Abstract
一种大豆咖啡西洋参生物活性肽的制备方法和应用，原料包括大豆、西洋参和咖啡，所述大豆、西洋参和咖啡的蛋白原料经胃蛋白酶和胰蛋白酶酶解制成，所述大豆、西洋参和咖啡肽的质量比为(1.3‑3.1)：(1.3‑2.2)：(1.8‑4.1)，所述大豆、西洋参和咖啡复合肽的质量比为(1.3‑4.0)：0.42；将大豆30‑50份，西洋参5‑15份，咖啡15‑40份比例混合，首先制备分离碱性蛋白溶液，将大豆、西洋参、咖啡分离，碱性溶液加入胃蛋白酶、胰蛋白酶、木瓜蛋白酶、木薯淀粉酶，酶解后，灭酶。本发明通过特定工艺制备获得了特定分子量区间的复合植物小分子大豆咖啡西洋参肽液，能够起到抗疲劳、抗衰老、抗休克、提高思维、改善记忆及调节内分泌、增强人体免疫力及改善心血管功能等作用。
Description
技术领域
本发明涉及大豆咖啡西洋参生物活性肽的制备领域，尤其涉及一种大豆咖啡西洋参生物活性肽的制备方法和应用。
背景技术
生物活性肽(Bioactive Peptides，BAP)是蛋白质中20种天然氨基酸以不同组成和排列方式构成的从二肽到复杂的线性、环形结构的不同肽类的总称，是源于蛋白质的多功能化合物。生物活性肽具有多种人体代谢和生理调节功能，易消化吸收，有促进免疫、激素调节、抗菌、抗病毒、降血压、降血脂等作用，是当前国际食品界最热门的研究课题和极具发展前景的功能因子。
现有的生物活性肽种类中并没有以大豆、西洋参和咖啡为原料的，导致生物活性肽的种类不够丰富，营养成分也不够多样，无法满足消费者的需求。
发明内容
针对现有技术中的上述不足，本发明提供了一种大豆咖啡西洋参生物活性肽的制备方法和应用。
为了达到上述发明目的，本发明采用的具体方案为：
一种大豆咖啡西洋参生物活性肽的制备方法，原料包括大豆、西洋参和咖啡，所述大豆、西洋参和咖啡的蛋白原料经胃蛋白酶和胰蛋白酶酶解制成，所述大豆、西洋参和咖啡肽的质量比为(1.3-3.1)：(1.3-2.2)：(1.8-4.1)，所述大豆、西洋参和咖啡复合肽的质量比为(1.3-4.0)：0.42。
进一步，具体方法为：将大豆30-50份，西洋参5-15份，咖啡15-40份比例混合，首先制备分离碱性蛋白溶液，将大豆、西洋参、咖啡分离，碱性溶液加入胃蛋白酶、胰蛋白酶、木瓜蛋白酶、木薯淀粉酶，酶解后，灭酶。
进一步，所述复合小分子离子肽液去除表面杂质，离心后所得上清液，即获得复合大豆西洋参咖啡小分子(离子)肽。
一种大豆咖啡西洋参生物活性肽的应用，按1％-5％的比列和纯净水调合，再加入调味剂、植物防腐剂、纯净水，得到原料，制成化妆品、食品或药品及保健品。
本发明的有益效果为：
本发明通过特定工艺制备获得了特定分子量区间的复合植物小分子大豆咖啡西洋参肽液。三者或四者在合适比例下组成合物，能够以较少的使用量，起到抗疲劳、抗衰老、抗休克、提高思维、改善记忆及调节内分泌、增强人体免疫力及改善心血管功能等作用。对促进淋巴细胞的转化，诱导免疫因子生成，增强集体免疫功能的作用。具有镇静、增强学习记忆、促进神经生长、抗惊厥、阵痛、解热的作用。具有抗心率失常、抗心肌缺血和再灌损伤等作用。具有抗溶血、止血、降低血液凝固性、抑制血小板凝聚、调血脂、抗动脉粥硬化、降低血糖等作用。具有抗利尿的作用。具有抑制癌细胞增殖、抑制单纯疱疹等病毒的作用。
具体实施方式
以下通过具体实施例进一步描述本发明，但本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内，对本发明进行的变更、组合或替换，对于本领域的技术人员来说是显而易见的，且包含在本发明的范围之内。
一种大豆咖啡西洋参生物活性肽的制备方法和应用，首先制备大豆和咖啡及西洋参按30-70份，5-15份，15-40份混合分离蛋白碱性溶液。将大豆、咖啡和西洋参分离碱性溶液加入Alcalase蛋白酶，酶解后，灭酶，离心，取得上清液，即为复合大豆咖啡西洋参肽液。在温室下对大豆西洋参咖啡肽液进行回流超滤操作，在超滤操作同时进行活性炭的吸附除臭。所述超滤操作采用9支超滤膜进行串联截留分子量为2500Da～4500Da，压力为0.2Mpa～1.2Mpa，处理5～20min，脱除相对分子质量≦2500Da的无机盐离子后，收集滤出大豆咖啡西洋参复合肽液。后在温室下加入橙子、草莓液等调味剂及低聚果糖、木糖醇、水果糖等改善成品复合肽液的口感。生产出具有保健和治疗为主的双重作用的口服液。
实施例1
原料组成(重量份)：复合大豆西洋参咖啡复合肽80份、结晶果糖和食品添加剂2份。
所述食品添加剂由以下原料按重量份混合而成：甜橙香精0.5份，降苦味香精0.5份，罗汉果甜苷0.4份，甜菊糖苷0.05份。
一种植物肽的制备方法，包括以下步骤：
S1.将复合大豆西洋参咖啡肽溶于水中(物料与水的质量比为1:10)，用1mol/LNaOH溶液调节溶液pH为8.5，加入碱性蛋白酶酶解，然后用1mol/L HC1溶液调节pH为7，加入中性蛋白酶酶解，添加量为2500U/kg，结束后灭酶，离心，取上清液，用截留分子量为1000u的超滤膜超滤，得到分子量小于1000u的滤过液，得到大豆西洋参咖啡复合低聚肽浓缩液。
S2.将大豆西洋参咖啡低聚肽混合，溶解于水中(物料与水的质量比为1:10)，用1mol/L HC1溶液调节pH为7，加入a-糜凝乳酶和风味蛋白酶反应，所述a-糜凝乳酶的添加量为2000U/kg，所述风味蛋白酶的添加量为3000U/kg，结束后灭酶，离心，取上清液，透析，-10℃温度下预冷50min，得到复合肽浓缩液，加入结晶果糖和食品添加剂，溶解混合均匀，制得植物肽口服液。
实施例3
原料组成(重量份)：大豆西洋参咖啡复合肽75份、结晶果糖15份和食品添加剂1.5份。
所述食品添加剂由以下原料按重量份混合而成：甜橙香精0.5份，降苦味香精0.5份，罗汉果甜苷0.4份，甜菊糖苷0.05份。
一种植物肽的制备方法，包括以下步骤：
S1.将大豆西洋参咖啡肽溶于水中(物料与水的质量比为1:10)，用1mol/L NaOH溶液调节溶液pH为8.5，加入碱性蛋白酶酶解，然后用1mol/L HC1溶液调节pH为7，加入中性蛋白酶酶解，添加量为2500U/kg，结束后灭酶，离心，取上清液，用截留分子量为1000u的超滤膜超滤，得到分子量小于1000u的滤过液，得到大豆西洋参咖啡复合低聚液态。
S2.将大豆西洋参咖啡低聚肽混合，溶解于水中(物料与水的质量比为1:10)，用1mol/L HC1溶液调节pH为6，加入a-糜凝乳酶和风味蛋白酶反应，所述a-糜凝乳酶的添加量为2000U/kg，所述风味蛋白酶的添加量为3000U/kg，结束后灭酶，离心，取上清液，得到复合肽浓缩液，加入结晶果糖和食品添加剂，溶解混合均匀，制得植物肽口服液。
对比例1
原料组成(重量份)：大豆西洋参咖啡复合肽75份、结晶果糖15份和食品添加剂1.5份。
所述食品添加剂由以下原料按重量份混合而成：甜橙香精0.5份，降苦味香精0.5份，罗汉果甜苷0.4份，甜菊糖苷0.05份。
一种植物肽的制备方法，包括以下步骤：
将大豆西洋参咖啡复合肽，加入结晶果糖和食品添加剂，溶解混合均匀，制得植物肽口服液。
对比例2
原料组成(重量份)：大豆西洋参咖啡复合肽75份、结晶果糖15份和食品添加剂1.5份。
所述食品添加剂由以下原料按重量份混合而成：甜橙香精0.5份，降苦味香精0.5份，罗汉果甜苷0.4份，甜菊糖苷0.05份。
一种植物肽的制备方法，包括以下步骤：
将大豆西洋参咖啡肽混合，溶解于水中(物料与水的质量比为1:10)，用1mol/LHC1溶液调节pH为6，加入a-糜凝乳酶和风味蛋白酶反应，所述a-糜凝乳酶的添加量为2000U/kg，所述风味蛋白酶的添加量为3000U/kg，结束后灭酶，离心，取上清液，加入结晶果糖和食品添加剂，溶解混合均匀，制得植物肽液口服液
以上所述仅为本发明专利的较佳实施例而已，并不用以限制本发明专利，凡在本发明专利的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明专利的保护范围之内。
Claims (4)
1.一种大豆咖啡西洋参生物活性肽的制备方法，其特征在于：原料包括大豆、西洋参和咖啡，所述大豆、西洋参和咖啡的蛋白原料经胃蛋白酶和胰蛋白酶酶解制成，所述大豆、西洋参和咖啡肽的质量比为(1.3-3.1)：(1.3-2.2)：(1.8-4.1)，所述大豆、西洋参和咖啡复合肽的质量比为(1.3-4.0)：0.42。
2.根据权利要求1所述的一种大豆咖啡西洋参生物活性肽的制备方法，其特征在于，具体方法为：将大豆30-50份，西洋参5-15份，咖啡15-40份比例混合，首先制备分离碱性蛋白溶液，将大豆、西洋参、咖啡分离，碱性溶液加入胃蛋白酶、胰蛋白酶、木瓜蛋白酶、木薯淀粉酶，酶解后，灭酶。
3.根据权利要求1所述的一种大豆咖啡西洋参生物活性肽的制备方法，其特征在于：所述复合小分子离子肽液去除表面杂质，离心后所得上清液，即获得复合大豆西洋参咖啡小分子(离子)肽。
4.一种大豆咖啡西洋参生物活性肽的应用，其特征在于：按1％-5％的比列和纯净水调合，再加入调味剂、植物防腐剂、纯净水，得到原料，制成化妆品、食品或药品及保健品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111544431.0A CN114214380A (zh) | 2021-12-16 | 2021-12-16 | 一种大豆咖啡西洋参生物活性肽的制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111544431.0A CN114214380A (zh) | 2021-12-16 | 2021-12-16 | 一种大豆咖啡西洋参生物活性肽的制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114214380A true CN114214380A (zh) | 2022-03-22 |
Family
ID=80703054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111544431.0A Pending CN114214380A (zh) | 2021-12-16 | 2021-12-16 | 一种大豆咖啡西洋参生物活性肽的制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114214380A (zh) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1489923A (zh) * | 2003-09-16 | 2004-04-21 | 北京陶正生物工程技术有限公司 | 大豆蛋白活性肽的制作方法 |
| CN104431208A (zh) * | 2014-12-29 | 2015-03-25 | 陕西天宝大豆食品技术研究所 | 肽咖啡及其制备方法 |
| CN108753894A (zh) * | 2018-06-21 | 2018-11-06 | 石丰 | 一种西洋参肽的提取方法 |
| CN108936692A (zh) * | 2018-06-21 | 2018-12-07 | 石丰 | 一种具有提高免疫力作用的西洋参肽的制备方法 |
| CN109845876A (zh) * | 2018-12-28 | 2019-06-07 | 广州合诚实业有限公司 | 具有独特溶解性能的高纯度大豆低聚肽及制备方法与应用 |
| CN110037163A (zh) * | 2019-04-24 | 2019-07-23 | 王书敏 | 一种复合植物蛋白肽的制备方法 |
| CN111358009A (zh) * | 2020-03-16 | 2020-07-03 | 赵秋萍 | 一种植物肽及其制备方法和应用 |
| CN111642666A (zh) * | 2020-06-05 | 2020-09-11 | 内蒙古科然生物高新技术有限责任公司 | 一种人参提取物大豆肽粉固体饮料的制备方法 |
| CN113080288A (zh) * | 2021-03-28 | 2021-07-09 | 广东亿盈新材料科技有限公司 | 小分子肽咖啡的制作方法 |
-
2021
- 2021-12-16 CN CN202111544431.0A patent/CN114214380A/zh active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1489923A (zh) * | 2003-09-16 | 2004-04-21 | 北京陶正生物工程技术有限公司 | 大豆蛋白活性肽的制作方法 |
| CN104431208A (zh) * | 2014-12-29 | 2015-03-25 | 陕西天宝大豆食品技术研究所 | 肽咖啡及其制备方法 |
| CN108753894A (zh) * | 2018-06-21 | 2018-11-06 | 石丰 | 一种西洋参肽的提取方法 |
| CN108936692A (zh) * | 2018-06-21 | 2018-12-07 | 石丰 | 一种具有提高免疫力作用的西洋参肽的制备方法 |
| CN109845876A (zh) * | 2018-12-28 | 2019-06-07 | 广州合诚实业有限公司 | 具有独特溶解性能的高纯度大豆低聚肽及制备方法与应用 |
| CN110037163A (zh) * | 2019-04-24 | 2019-07-23 | 王书敏 | 一种复合植物蛋白肽的制备方法 |
| CN111358009A (zh) * | 2020-03-16 | 2020-07-03 | 赵秋萍 | 一种植物肽及其制备方法和应用 |
| CN111642666A (zh) * | 2020-06-05 | 2020-09-11 | 内蒙古科然生物高新技术有限责任公司 | 一种人参提取物大豆肽粉固体饮料的制备方法 |
| CN113080288A (zh) * | 2021-03-28 | 2021-07-09 | 广东亿盈新材料科技有限公司 | 小分子肽咖啡的制作方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103598544B (zh) | 以大蒜为原料进行综合利用的提取工艺 | |
| US20220024974A1 (en) | Methods for producing a rice protein peptide and applications thereof | |
| KR101254403B1 (ko) | 발효 콜라겐 펩타이드 제조 방법 | |
| WO2020238151A1 (zh) | 一种咸味增强肽及其制备方法和用途 | |
| CN111642666A (zh) | 一种人参提取物大豆肽粉固体饮料的制备方法 | |
| CN108546281A (zh) | 一种人参低聚肽及其制备方法和应用 | |
| CN111772194A (zh) | 补气安神、益精固肾的食品配方 | |
| CN103876163A (zh) | 一种林蛙肉复合蛋白粉及其制备方法 | |
| CN108094674A (zh) | 一种冷冻干燥技术制备大豆肽的方法 | |
| CN109757601B (zh) | 一种海参肽及其生产方法 | |
| CN111329988A (zh) | 一种富含游离精氨酸的阿胶肽含片及其制备方法 | |
| CN114214380A (zh) | 一种大豆咖啡西洋参生物活性肽的制备方法和应用 | |
| CN101130801A (zh) | 一种降血压活性肽产品的制备 | |
| CN110499351A (zh) | 一种具有高ace抑制活性的大豆肽及其制备方法与应用 | |
| CN110810852A (zh) | 一种调节心血管功能的蚯蚓冻干粉的制备方法 | |
| CN109457008A (zh) | 一种人参螯合肽的制备方法 | |
| CN104757655A (zh) | 一种地龙氨基酸饮料及其制作方法 | |
| CN114438155A (zh) | 一种大豆咖啡枸杞生物活性肽的制备方法和应用 | |
| CN114395596A (zh) | 一种大豆咖啡灵芝生物活性肽的制备方法和应用 | |
| CN114480540A (zh) | 一种大豆咖啡山楂生物活性肽的制备方法和应用 | |
| CN114480536A (zh) | 一种大豆咖啡黄精生物活性肽的制备方法和应用 | |
| CN114480539A (zh) | 一种大豆咖啡人参生物活性肽的制备方法和应用 | |
| CN114231583A (zh) | 一种大豆咖啡三七生物活性肽的制备方法和应用 | |
| CN114517219A (zh) | 一种大豆咖啡天麻生物活性肽的制备方法和应用 | |
| JP2589286B2 (ja) | ビフィズス菌増殖促進剤及びこれを用いた発酵乳の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220322 |
|
| RJ01 | Rejection of invention patent application after publication |